ATE355380T1 - Methode zur selektiven inaktivierung der viralen replication - Google Patents

Methode zur selektiven inaktivierung der viralen replication

Info

Publication number
ATE355380T1
ATE355380T1 AT94912387T AT94912387T ATE355380T1 AT E355380 T1 ATE355380 T1 AT E355380T1 AT 94912387 T AT94912387 T AT 94912387T AT 94912387 T AT94912387 T AT 94912387T AT E355380 T1 ATE355380 T1 AT E355380T1
Authority
AT
Austria
Prior art keywords
virus
viral replication
rna
agent
selective inactivation
Prior art date
Application number
AT94912387T
Other languages
English (en)
Inventor
Vincent J Miles
Michael B Mathews
Michael G Katze
Gary Witherell
Julia C Watson
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE355380T1 publication Critical patent/ATE355380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94912387T 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication ATE355380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4202493A 1993-04-02 1993-04-02

Publications (1)

Publication Number Publication Date
ATE355380T1 true ATE355380T1 (de) 2006-03-15

Family

ID=21919634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912387T ATE355380T1 (de) 1993-04-02 1994-04-01 Methode zur selektiven inaktivierung der viralen replication

Country Status (8)

Country Link
US (2) US5738985A (de)
EP (1) EP0693126B9 (de)
JP (2) JP3901726B2 (de)
AT (1) ATE355380T1 (de)
AU (1) AU6497694A (de)
CA (1) CA2159639A1 (de)
DE (1) DE69434931T2 (de)
WO (1) WO1994023041A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US6824976B1 (en) * 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
CA2172824A1 (en) * 1993-10-25 1995-05-04 Charles M. Moehle Methods for screening for antimycotics
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
GB9420735D0 (en) * 1994-10-14 1994-11-30 Karobio Ab Reporter cell line
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
WO1997039119A1 (en) * 1996-04-15 1997-10-23 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
JP2001514508A (ja) 1997-03-05 2001-09-11 ユニバーシティー オブ ワシントン Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999019496A1 (en) * 1997-10-16 1999-04-22 Temple University - Of The Commonwealth System Of Higher Education Inhibition of human immunodeficiency virus (hiv-1) replication
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7019195B1 (en) * 1998-05-26 2006-03-28 Syngenta Participations Ag Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
GB9820025D0 (en) * 1998-09-14 1998-11-04 Pfizer Ltd Assay
CA2280276A1 (en) * 1998-09-14 2000-03-14 Pfizer Inc. Assay for detecting modulators of serine/threonine phosphatase activity
US6562571B1 (en) 1999-05-25 2003-05-13 University Of Rochester Human heme-regulated initiation factor 2-α kinase
US6448007B1 (en) 1999-07-02 2002-09-10 Message Pharmaceuticals Functional genomic screen for post-transcriptional 5′ and 3′ regulatory elements
US6632800B1 (en) 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US7482425B2 (en) * 1999-08-26 2009-01-27 Amylin Pharmaceuticals, Inc. Compositions for lipid matrix-assisted chemical ligation
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
EP1235842A4 (de) * 1999-10-15 2003-04-23 Univ Massachusetts Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
WO2001051183A1 (en) * 2000-01-07 2001-07-19 Proteros, Llc. Enhanced faraday cup for diagnostic measurements in an ion implanter
WO2001084155A1 (en) 2000-04-28 2001-11-08 Message Pharmaceuticals, Inc. Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1176196A1 (de) * 2000-07-24 2002-01-30 Message Pharmaceuticals, Inc. Funktionalle genomische Selektion für post-transkriptionale 5' und 3' Regulationselemente
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
FR2815358A1 (fr) * 2000-10-17 2002-04-19 Parteurop Dev Polypeptides inhibiteurs de l'ires du virus de l'hepatite c et procede de criblage desdits polypeptides
US6420107B1 (en) * 2001-07-24 2002-07-16 University Of North Dakota Assay for identifying anti-viral agents specific for protein-coated double-stranded DNA viruses
DE10143106C1 (de) * 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
EP1451348B1 (de) * 2001-09-10 2015-08-12 Meso Scale Technologies, LLC Verfahren, reagentien, kits und vorrichtungen zur proteinfunktionsanalyse
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AU2002360417A1 (en) * 2001-11-26 2003-06-10 Duke University Genetically stable expression vector
WO2003063888A1 (en) * 2002-01-30 2003-08-07 Robertson Hugh D Antiviral compositions and methods for identification and use
US7514082B2 (en) 2002-02-01 2009-04-07 Immunemed, Inc. Anti-viral VSF protein and hybridoma producing the same
US20030219723A1 (en) * 2002-05-20 2003-11-27 Lu Henry H. Compositions and methods for screening and identifying anti-HCV agents
US20060110404A1 (en) * 2002-09-13 2006-05-25 Smithkline Beecham Corporation Set of ubiquitous cellular proteins involved in viral life cycle
US6821744B2 (en) 2002-10-29 2004-11-23 Roche Diagnostics Operations, Inc. Method, assay, and kit for quantifying HIV protease inhibitors
FR2848572B1 (fr) * 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
ATE554185T1 (de) * 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen
WO2005013905A2 (en) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
US20050164167A1 (en) * 2004-01-28 2005-07-28 Buscher Benjamin A. Method of discovery and development of broad-spectrum antiviral drugs
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
TWI286574B (en) * 2004-07-27 2007-09-11 Univ Chung Yuan Christian Use of bicistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US7588885B2 (en) * 2004-08-06 2009-09-15 Chung Yuan Christian University Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
HRP20070435A9 (en) * 2005-02-28 2008-09-30 Genelabs Technologies Tricyclic-nucleoside compounds for treating viral infections
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2008546802A (ja) * 2005-06-24 2008-12-25 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルスを治療するためのヘテロアリール誘導体
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
AU2006287530A1 (en) * 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
BRPI0619733A2 (pt) * 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 6 membros)-amido
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
JP2009528670A (ja) * 2006-06-02 2009-08-06 財団法人高知県産業振興センター 半導体機器及びその製法
PE20081113A1 (es) * 2006-07-20 2008-10-03 Genelabs Tech Inc Inhibidores virales policiclicos
WO2008064304A2 (en) * 2006-11-22 2008-05-29 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
US8057798B2 (en) 2007-02-02 2011-11-15 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
CN101842098A (zh) * 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
ATE553764T1 (de) * 2007-09-14 2012-05-15 Trana Discovery Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
US8695094B2 (en) * 2008-06-24 2014-04-08 International Business Machines Corporation Detecting secondary infections in virus scanning
CA2776044A1 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
EP2588455B1 (de) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-essigsäure derivate als hiv antivirale verbindungen
EA201300160A1 (ru) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
JP5944901B2 (ja) 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
TWI448538B (zh) 2012-10-23 2014-08-11 Ind Tech Res Inst 螢光材料與紫外光發光裝置
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
AU2016258194B2 (en) * 2015-05-06 2019-01-03 The Procter & Gamble Company Detection of oral microbial virulence factors
GB202016650D0 (en) * 2020-10-20 2020-12-02 Primer Design Ltd Kit and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092574B1 (de) * 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonukleotides heilmittel und dessen herstellungsverfahren
GB8911555D0 (en) * 1989-05-19 1989-07-05 Inglis Stephen C Ribosomal frame-shift signals and uses
HUT63430A (en) * 1990-08-16 1993-08-30 Isis Pharmaceuticals Inc Process for producing oligonucleotides influencing the effect of cytomegalovirus infection
DK0598029T3 (da) * 1991-08-07 2002-05-27 W French Anderson Retrovirale vektorer indeholdende interne ribosome indgangssteder

Also Published As

Publication number Publication date
WO1994023041A3 (en) 1995-01-05
CA2159639A1 (en) 1994-10-13
EP0693126B9 (de) 2007-09-12
US6156496A (en) 2000-12-05
EP0693126B1 (de) 2007-02-28
WO1994023041A2 (en) 1994-10-13
JP3901726B2 (ja) 2007-04-04
EP0693126A1 (de) 1996-01-24
JP2007075116A (ja) 2007-03-29
DE69434931T2 (de) 2007-11-22
HK1009980A1 (en) 1999-06-11
AU6497694A (en) 1994-10-24
JPH08509213A (ja) 1996-10-01
DE69434931D1 (de) 2007-04-12
US5738985A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
DK0891420T4 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DE50214416D1 (de) Vermehrung von viren in zellkultur
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
SE8405133L (sv) Anti-viralt medel
DE3486160D1 (de) Modifizierte lebende pseudo-rabies-viren, diese enthaltende impfstoffe gegen pseudo-rabies, verfahren zur herstellung und verfahren zur verwendung derselben.
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
PT842276E (pt) Metodo para a reproducao in vitro das actividades de rna polimerase dependente de rna e nucleotidil-transferase terminal codificadas pelo virus da hepatite c (hcv)
DE69128077D1 (de) Nuklein-säure amplifikation mit dns abhängigen rns polymerasen aktivität von rns-replikasen
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
DK1126859T3 (da) Blodleukocyt-aferese til behandling af HIV
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
ES2175462T3 (es) Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.
ES2188760T3 (es) Oligonucleotidos especificos para el virus de la hepatitis b.
DE59103696D1 (de) Biomasse zur produktion von virus/virusantigen.
ATE199538T1 (de) Antivirusverbindungen
DE58904809D1 (de) Plasma-roentgenroehre, insbesondere zur roentgen-vorionisierung von gaslasern, und verwendung als elektronenkanone.
FI880960L (fi) Anvaendning av rnas l inhibitor som markeringsaemne i virusinfektioner.
EP0227604A3 (de) Verwendung von Oligopeptiden in der Behandlung von viralen Infektionen
DE69704229D1 (de) Antivirusverbindungen
ATE255594T1 (de) Hepatitis b inhibitoren
DE69705583D1 (de) Antivirusverbindungen
ATE318893T1 (de) Verbesserte replikation von hcv rna

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties